Table 1 Baseline characteristics of subjects
| Â | Progressors (n=26) | Regressors (n=24) | p value |
|---|---|---|---|
Age (years) | 69 ± 10 | 66 ± 10 | 0.28 |
Men | 22 (85%) | 17 (71%) | 0.31 |
Body mass index (kg/m2) | 24.3 ± 2.5 | 26.5 ± 4.8 | 0.06 |
eGFR (ml/min/1.73m2) | 63.4 ± 14.1 | 63.7 ± 15.9 | 0.94 |
Hypertension | 21 (81%) | 14 (58%) | 0.12 |
Smoker | 8 (31%) | 3 (13%) | 0.28 |
Pitavastatin/Pravastatin | 8 (31%)/18 (69%) | 12 (50%)/12 (50%) | 0.17 |
Stable AP/Unstable AP | 18 (69%)/8 (31%) | 17 (71%)/7 (29%) | 0.9 |
Target coronary artery | Â | Â | 0.84 |
Left anterior descending | 12 (46%) | 13 (54%) | Â |
Left circumflex | 1 (4%) | 1 (4%) | Â |
Right | 13 (50%) | 10 (42%) | Â |
Types of stent | Â | Â | >0.99 |
Bare metal stent | 3 (12%) | 3 (12.5%) | Â |
Drug-eluting stent | 23 (88%) | 21 (87.5%) | Â |
Medications | Â | Â | Â |
Aspirin | 26 (100%) | 23 (96%) | 0.48 |
Thienopyridines | 26 (100%) | 24 (100%) | - |
ACE inhibitors or ARBs | 17 (65%) | 12 (50%) | 0.27 |
β Blockers | 1 (4%) | 2 (8%) | 0.6 |
Calcium channel blockers | 16 (62%) | 11 (46%) | 0.27 |
Insulin | 8 (31%) | 3 (13%) | 0.18 |
Thiazolidine | 3 (12%) | 3 (13%) | >0.99 |
Follow-up duration (days) | 236 ± 32 | 231 ± 28 | 0.58 |